ES2147966T3 - Derivados de guanidina sustituida y su uso como inhibidores del intercambio de na+/h+. - Google Patents

Derivados de guanidina sustituida y su uso como inhibidores del intercambio de na+/h+.

Info

Publication number
ES2147966T3
ES2147966T3 ES97302773T ES97302773T ES2147966T3 ES 2147966 T3 ES2147966 T3 ES 2147966T3 ES 97302773 T ES97302773 T ES 97302773T ES 97302773 T ES97302773 T ES 97302773T ES 2147966 T3 ES2147966 T3 ES 2147966T3
Authority
ES
Spain
Prior art keywords
inhibitors
guanidine derivatives
substituted guanidine
exchange
diseases caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97302773T
Other languages
English (en)
Inventor
Masahumi Kitano
Kazuhiro Nakano
Naohito Ohashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of ES2147966T3 publication Critical patent/ES2147966T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

LOS DERIVADOS DE GUANIDINA SUSTITUIDA DE FORMULA (1), EN LA QUE CADA UNO DE R{SUB,1} A R{SUB,4} Y Z ES UN GRUPO ORGANICO, M ES 0, 1 O 2, E Y{SUB,1}, Y{SUB,2}, Y{SUB,3} E Y{SUB,4} FORMAN JUNTO CON EL ATOMO DE CARBONO AL CUAL SE ENCUENTRAN UNIDOS UN ANILLO HETEROCICLICO O CARBOCICLICO, SATURADO O INSATURADO, Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, SON INHIBIDORES DEL SISTEMA DE TRANSPORTE DE INTERCAMBIO DE SODIO/PROTON (NA{SUP,+}/H{SUP,+}, Y POR TANTO PUEDEN UTILIZARSE EN EL TRATAMIENTO O LA PROFILAXIS, POR EJEMPLO DE LA HIPERTENSION, LAS ARRITMIAS, LA ANGINA DE PECHO, LA HIPERTROFIA CARDIACA, LA DIABETES MELITUS, LOS TRASTORNOS DE ORGANOS ASOCIADOS CON ISQUEMIA O CON REPERFUSION ISQUEMICA, LOS TRASTORNOS CEREBROISQUEMICOS, LAS ENFERMEDADES PROVOCADAS POR UNA PROLIFERACION CELULAR EXCESIVA, Y LAS ENFERMEDADES PROVOCADAS POR LESIONES DE LAS CELULAS ENDOTELIALES.
ES97302773T 1996-04-24 1997-04-23 Derivados de guanidina sustituida y su uso como inhibidores del intercambio de na+/h+. Expired - Lifetime ES2147966T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8128973A JPH09291076A (ja) 1996-04-24 1996-04-24 置換グアニジン誘導体およびその製法

Publications (1)

Publication Number Publication Date
ES2147966T3 true ES2147966T3 (es) 2000-10-01

Family

ID=14997991

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97302773T Expired - Lifetime ES2147966T3 (es) 1996-04-24 1997-04-23 Derivados de guanidina sustituida y su uso como inhibidores del intercambio de na+/h+.

Country Status (6)

Country Link
US (1) US5814654A (es)
EP (1) EP0803501B1 (es)
JP (1) JPH09291076A (es)
AT (1) ATE194327T1 (es)
DE (1) DE69702419T2 (es)
ES (1) ES2147966T3 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
CA2195697A1 (en) * 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
EP1056729B1 (en) 1998-02-27 2004-12-29 Pfizer Products Inc. N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia
AU4360200A (en) 1999-04-23 2000-11-10 Bristol-Myers Squibb Company Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
AU1733701A (en) * 1999-12-16 2001-06-25 Sumitomo Pharmaceuticals Company, Limited Substituted guanidine derivatives
US20050261164A1 (en) * 2002-07-09 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Remedy for urinary frequency and urinary incontinence
CN113527672B (zh) * 2020-03-30 2022-09-20 复旦大学 一种胍基衍生物及其基因递释系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604852A1 (de) * 1992-12-28 1994-07-06 Hoechst Aktiengesellschaft 2,4-Substituierte 5-(N-substituierte-Sulfamoyl)-Benzoylguanidine, als Antiarrythmika, Inhibitoren der Proliferationen von Zellen, und Inhibitoren des Natrium-Protonen-Antiporters
CA2121391A1 (en) * 1993-04-28 1994-10-29 Atsuyuki Kojima Indoloylguanidine derivatives
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2160600A1 (en) * 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
US5627193A (en) * 1995-02-09 1997-05-06 Mitsui Toatsu Chemicals, Inc. Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds

Also Published As

Publication number Publication date
EP0803501B1 (en) 2000-07-05
EP0803501A1 (en) 1997-10-29
ATE194327T1 (de) 2000-07-15
JPH09291076A (ja) 1997-11-11
DE69702419T2 (de) 2000-12-14
DE69702419D1 (de) 2000-08-10
US5814654A (en) 1998-09-29

Similar Documents

Publication Publication Date Title
ES2147966T3 (es) Derivados de guanidina sustituida y su uso como inhibidores del intercambio de na+/h+.
ES2117759T3 (es) Derivados de indoloilguanidina como inhibidores del intercambio sodio-hidrogeno.
PE27499A1 (es) Derivados del 2-(purin-9-il)-tetrahidrofuran-3,4-diol
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
ES2081747B1 (es) Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
AR055616A1 (es) Compuestos de tiofeno bencimidazol
BR0007229A (pt) Aminoazaciclos heterocìclicos substituìdos úteis como agentes de sistema nervoso central
DK1113011T3 (da) Aminotetrazol-derivater, der er anvendelige som nitrogenoxidsynthaseinhibitorer
ES2164366T3 (es) Derivados de la distamicina acriloil sustituidos, procedimiento de fabricacion asociado y su utilizacion como agentes antitumorales y antivirales.
DE60011110D1 (de) Pharmazeutisch wirksame sulfonyl hydrazid-derivate
NO330989B1 (no) Nye piperazinderivater, fremgangsmater for fremstilling av slike og deres anvendelse som syntesemellomprodukter.
MX2007005469A (es) Derivados tric??clicos de guanidina como inhibidores del intercambio de sodio-prot??n.
AR009435A1 (es) Derivado de guanaidina n-[carbonil(heteroaril-substituida de 5 miembros)], un inhibidor del intercambiador de na+/h+ que comprende dicho derivado y usosen la fabricacion de medicamentos.
ES2057065T3 (es) Composicion mejoradora de la dismnesia.
CO4970779A1 (es) Derivados del acido aminoetilfenoxiacetico y agentes para reducir el dolor y promover la eliminacion de calculos en urolitiasis
BR0110255A (pt) Cromenilmetil pirimidinadiaminas como agentes antibacterianos
ES2106162T3 (es) Derivados del acido butirico, procedimiento para su preparacion y su empleo como pesticidas.
AR027578A1 (es) Derivados de indano
SE7811455L (sv) 2-imino-imidazolidin-derivat
DE69425970D1 (de) Benzol-derivate, verwendbar für ischämische erkrankungen
GB2341861A (en) Substituted imidazole derivatives and their use as histamine H 3 receptor ligands
PE20020339A1 (es) Derivados de pirrolidin como inhibidores de las metaloproteasas
AR038380A1 (es) 2 ' -halo-3 ' , 5 ' -dialcoxi-fen-1' -il-imino-2-imidazolidinas y su uso como un farmaco
PE20020484A1 (es) Derivados de pirimidina como inhibidores de la enzima conversor de endotelina
ES2036600T3 (es) Procedimiento para preparar 1-(3-(2-dialquilaminoetoxi)-2-tienil)-3-fenil-1-propanonas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 803501

Country of ref document: ES